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Abstract: Kaempferol is a widely distributed dietary flavonoid. Epidemiological studies have
demonstrated kaempferol consumption lowers the risk of ovarian cancer. Our previous research
proved that kaempferol suppresses human ovarian cancer cells by inhibiting tumor angiogenesis.
However, the effects of kaempferol on the cell cycle and extrinsic apoptosis of ovarian cancer cells have
not yet been studied. In the present study, we demonstrated that kaempferol induced G2/M cell cycle
arrest via the Chk2/Cdc25C/Cdc2 pathway and Chk2/p21/Cdc2 pathway in human ovarian cancer
A2780/CP70 cells. Chk2 was not responsible for kaempferol-induced apoptosis and up-regulation
of p53. Kaempferol stimulated extrinsic apoptosis via death receptors/FADD/Caspase-8 pathway.
Our study suggested that Chk2 and death receptors played important roles in the anticancer activity
of kaempferol in A2780/CP70 cells. These findings provide more evidence of the anti-ovarian cancer
properties of kaempferol and suggest that kaempferol could be a potential candidate for ovarian
cancer adjuvant therapy.
Keywords: kaempferol; cell cycle arrest; Chk2; apoptosis; DR5; Fas
1. Introduction
Kaempferol (Figure 1A) is a widely distributed natural flavonoid. It occurs not only in
various fruits and vegetables (e.g., apples, berries, broccoli), but also in many traditional medical
herbs (e.g., Kaempferia rotunda L., Hedyotis diffusa Willd, Hypericum perforatum). Numerous studies
have demonstrated that kaempferol and some kinds of kaempferol glycosides exert a wide range
of physiological activities, including antioxidant, anti-inflammatory, anti-microbial, anticancer,
anti-diabetic, and anti-obesity activities [1].
Recently, an epidemiological study has shown that kaempferol consumption is associated with
a linear decline in ovarian cancer risk [2]. Ovarian cancer is a gynecological cancer with poor prognosis.
The estimated new ovarian cancer cases and deaths in the United States in 2018 are 22,240 and 14,070,
respectively [3]. Most ovarian cancer patients die because of delayed diagnosis or recurrent disease [4].
Cytoreductive surgery with chemotherapy is the standard of care for ovarian cancer. However,
the present treatment rarely works in patients with advanced-stage or recurrent ovarian cancer,
and may cause severe systemic toxicity [5]. Therefore, it is essential to develop more efficient and safer
cancer treatments. Flavonoids, a class of plant secondary metabolites, are regarded as prospective
Molecules 2018, 23, 1095; doi:10.3390/molecules23051095 www.mdpi.com/journal/molecules
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compounds for cancer prevention and anticancer therapy because of their high effectiveness and few
side effects [6,7]. Checkpoint kinase 2 (Chk2) and death receptors have been reported to be the targets
of flavonoids [8–11].
Chk2, a stable serine/threonine kinase expressed throughout the cell cycle, is a tumor suppressor
which regulates multiple fundamental cellular functions [12]. Mutations and/or deletions of Chk2
have been linked to a wide range of cancers [12]. Chk2 can be phosphorylated at threonine 68 and
activated in response to DNA damage [13]. Active Chk2 acts as a signal transducer and phosphorylates
a variety of substrates, such as the Cdc25 phosphatases, p53 and E2F1, which are associated with the
induction of the cell cycle arrest, the initiation of DNA repair, and the activation of apoptosis [14].
Death receptors are members of the tumor necrosis factor receptor superfamily characterized
by a cytoplasmic region known as the “death domain” [15]. DR5 (also known as TRAILR2) and Fas
(also known as CD95) belong to the death receptor family. The binding of death receptors with their
corresponding ligands results in the transduction of apoptotic and/or survival signals. For DR5 and
Fas, they only activate apoptotic pathways [16]. Up-regulation of death receptors is not only a common
strategy shared by many chemotherapy drugs to induce apoptosis of cancer cells [17,18], but also is
related to overcoming drug resistance of cancer cells [19,20].
Our previous research revealed that kaempferol induced human ovarian cancer cells through
activating the p53 pathway [21] and decreasing angiogenesis through ERK-NFκB-cMyc-p21 pathway [22].
In this study, we investigated whether kaempferol could interrupt the cell cycle and trigger extrinsic
apoptosis in human ovarian cancer A2780/CP70 cells. The possible underlying mechanisms were
also explored.
2. Results
2.1. Kaempferol Inhibits the Viability of A2780/CP70 Cells
To assess cell viability, the CellTiter 96® Aqueous One Solution Cell Proliferation Assay was
performed. Kaempferol dose-dependently inhibited the viability of human ovarian cancer A2780/CP70
cells. When treated with 40 µM kaempferol for 48 h, the viability of A2780/CP70 cells was reduced to
59% (Figure 1B). Meanwhile, kaempferol elicited less cytotoxicity to human normal ovarian epithelial
IOSE 364 cells (Figure 1B).
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Figure 1. Kaempferol preferentially inhibited the viability of human ovarian carcinoma A2780/CP70
cells. (A) Chemical structure of kaempferol; (B) The effects of keampferol on the viability of A2780/CP70
cells and IOSE-364 cells. * P < 0.05 compared with the control group.
2.2. Kae pferol Induces G2/ Cell Cycle Arrest in A2780/CP70 Cells
To easure the cell cycle distribution of A2780/CP70 cells after kae pferol treat ent, cells
were stained by PI and analyzed using flow cyto etry. Cell cycle analysis revealed that kae pferol
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effectively induced an increased population of cells in the G2/M phase, suggesting kaempferol led to
G2/M cell cycle arrest in A2780/CP70 cells (Figure 2A,B).
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Figure 2. Kaempferol induced G2/M cell cycle arrest in A2780/CP70 cells via Chk2. (A,B) Flow cytometry
assays revealed that kaempferol induced G2/M cell cycle arrest in A2780/CP70 cells; (C) Kaempferol
increased the expression of p-Chk2, p-Cdc25C, p21 and p-Cdc2, but had no influence on the
expression of Cyclin B1 in A2780/CP70 cells; (D) Knockdown of Chk2 attenuated kaempferol-induced
up-regulation of p-Chk2, p-Cdc25C, p21 and p-Cdc2, but had no effect on the expression of p53 and
cleavage of PARP-1 in A2780/CP70 cells. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
served as the loading control. Ctrl is short for control.
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2.3. Kaempferol Induces Cell Cycle Arrest via Chk2
The cell cycle is driven by cyclin dependent kinases (CDKs) that associate with cyclin regulatory
proteins at different points of the cell cycle. The activity of the Cyclin B1-Cdc2 complex is pivotal in the
G2/M transition. Cdc2 is activated via dephosphorylating at Tyr15 and Thr14 during progression into
mitosis. Cdc25C, which can be phosphorylated at Ser216 and inactivated by active Chk2, is a protein
phosphatase responsible for activating Cdc2. P21, which can be induced by activation of Chk2 in
a p53-independent manner [23], is another regulator of Cdc2 [24].
Western blot analysis demonstrated that the expression of p21 and the phosphorylation of Chk2,
Cdc25C, and Cdc2 were dramatically enhanced after kaempferol treatment in A2780/CP70 cells
(Figure 2C). The expression of Cyclin B1 was not influenced by kaempferol (Figure 2C). These results
implied that kaempferol might induce G2/M cell cycle arrest by up-regulating the expression of p21
and inactivating G2/M phase-related proteins Cdc25C and Cdc2 through activating Chk2.
To explore the role of Chk2 in kaempferol-mediated G2/M cell cycle arrest in A2780/CP70 cells,
Chk2 siRNA was transfected into A2780/CP70 cells to block the expression of Chk2. Knockdown of
Chk2 partially abrogated kaempferol-induced up-regulation of p-Chk2, p-Cdc25C, p21 and p-Cdc2
(Figure 2D). The result indicated that kaempferol halted the cell cycle progression at G2/M phase via
the Chk2/ Cdc25C/ Cdc2 pathway and Chk2/ p21/ Cdc2 pathway in A2780/CP70 cells.
2.4. Kaempferol Stimulates Apoptosis in A2780/CP70 Cells
Apoptosis is a form of programmed cell death [25]. The intrinsic (mitochondria-mediated) and
extrinsic (receptor-mediated) pathways are two major apoptotic pathways. Caspase-8 and Caspase-9
are key initial caspases in the extrinsic apoptotic pathway and intrinsic apoptotic pathway, respectively.
Activation of initial caspases leads to activation of effector caspases (e.g., Caspase-3 and Caspase-7)
and cleavage of PARP-1.
The result of flow cytometry assays revealed that kaempferol induced apoptosis in A2780/CP70
cells. The late apoptotic rate of A2780/CP70 cells was significantly increased to 23.95% when treated
with 40 µM kaempferol for 48 h (Figure 3A,B). In accordance with the result of the flow cytometry
assays, kaempferol significantly enhanced the cleavage of PARP-1 and the activity of Caspase-3/7,
-8 and -9, respectively (Figure 3C). These results suggested that kaempferol induced apoptosis in
A2780/CP70 cells via intrinsic and extrinsic pathways.Molecules 2018, 23, x 5 of 13 
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Figure 3. Kaempferol activated apoptosis in A2780/CP70 cells. (A,B) Flow Cytometry assays
demonstrated that kaempferol induced apoptosis (mainly late apoptosis) in A2780/CP70 cells. N, LA, L
and EA are short for necrotic cells, late apoptotic cells, living cells, and early apoptotic cells. (C) Kaempferol
enhanced the activity of Caspase-3/7, -8 and -9 in A2780/CP70 cells. (D) Kaempferol promoted the
expression of Fas, DR5, FADD, and cleaved PARP-1 in A2780/CP70 cells. (E–G) Knockdown of DR5
attenuated kaempferol-induced up-regulation of DR5, FADD and cleaved PARP-1, as well as the
activation of Caspase-3/7 and Caspase-8. GAPDH served as the loading control. * P < 0.05 compared
with control or between specific groups. Ctrl is short for control.
2.5. Kaempferol Initiates Apoptosis Not via Chk2 but via Death Receptors
It has been demonstrated that Chk2 can promote apoptosis in a p53-dependent manner. In the
p53-dependent pathway, activated Chk2 mediates apoptosis through stabilizing and stimulating
p53 [26,27]. Our previous work showed that kaempferol could induce intrinsic apoptosis via p53 [21].
To study whether Chk2 was involved in kaempferol-induced apoptosis, A2780/CP70 cells were
transfected with Chk2 siRNA. Western blot analysis revealed that kaempferol-induced upregulation of
p53 and cleavage of PARP-1 was not influenced by the knockdown of Chk2 (Figure 2D), suggesting that
Chk2 was not involved in the kaempferol-induced apoptosis of A2780/CP70 cells and that kaempferol
modulated the expression of p53 independently of Chk2.
As kaempferol enhanced the activity of Caspase-8, a key caspase in the extrinsic apoptotic
pathway, we hypothesized that kaempferol might have an impact on the expression of death receptors
and adaptor proteins. Western blot analysis showed that kaempferol increased the expression of two
death receptors, DR5 and Fas, and one adaptor protein, FADD (Figure 3D). Blocking DR5 partially
reversed kaempferol-induced up-regulation of the expression of FADD and activation of Caspase-3/7
and Caspase-8 (Figure 3E–G). Our data illustrated that kaempferol mediated apoptosis via death
receptors/ FADD/ Caspase-8 pathway in A2780/CP70 cells.
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2.6. Kaempferol Inhibits Ovarian Cancer OVCAR-3 Cells
To explore whether the anti-ovarian cancer activities of kaempferol were universal, we tested the
inhibitory effects of kaempferol on another ovarian cancer cell line OVCAR-3. Results showed that
the viability of OVCAR-3 cells was reduced to 60% under the treatment of 40 µM kaempferol for 48 h
(Figure 4A).Molecules 2018, 23, x 7 of 13 
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Kaempferol induced G2/M cell cycle arrest in a dose-dependent manner in OVCAR-3 cells
(Figure 4B,C). Western blot assay revealed that kaempferol elevated the expression of p21 and activated
the phosphorylation of Chk2, Cdc25C, and Cdc2 (Figure 4D). Meanwhile, it lowered the expression of
Cyclin B1.
Kaempferol triggered apoptosis in OVCAR-3 cells. The results of flow cytometry illustrated
that the percentages of early apoptotic cells and late apoptotic cells were significantly increased
in kaempferol-treated cells (Figure 4E,F), respectively. Kaempferol lifted the activities of caspases
(Figure 4G). Kaempferol increased the expression of Fas, DR5, and cleaved PARP-1 (Figure 4H).
In general, kaempferol had a suppressive effect on OVCAR-3 cells. The main mechanisms were
similar to the mechanisms of kaempferol on A2780/CP70 cells.
3. Discussion
Despite the improvement in diagnosis and treatment, cancer is still one of the most fatal
diseases. Surgery, chemotherapy, and radiation therapy are three standard types of cancer treatment.
Recently, hormonal therapy and targeted therapy have been used to treat various cancers. However,
current cancer therapies have drawbacks. The traditional therapies might cause severe adverse side
effects in patients. The newly developed therapies can only be applied to treat certain types of cancer.
Thus, it’s necessary to find novel treatments or adjuvant therapies for treating cancer.
Flavonoids are regarded as promising anticancer agents. Some dietary flavonoids have cytotoxicity
against various cancers, but have little or no side effects on normal cells. Kaempferol, a dietary flavonoid
widely existing in vegetables and fruits, has anticancer activity. Our previous studies showed that
kaempferol induced intrinsic apoptosis via activating p53 [21]. P53 is a major tumor suppressor whose
function is critical for anticancer effects. However, loss and/or mutation of p53 is very common in
human cancers [28]. Thus, we explored whether kaempferol had anticancer targets other than p53.
Chk2 emerges as an important signal transducer of cellular responses and a candidate tumor
suppressor [29]. Activation of Chk2 leads to the phosphorylation of over 20 proteins. Cell cycle arrest,
apoptosis, senescence, and DNA repair or tolerance of damage are induced by activation of Chk2
depending on the extent of damage, the cell type, and other factors [30].
Cdc25C and p21 are two down-stream proteins of Chk2. Both of them regulate the activity
of Cdc2. Some flavonoids and isoflavones exert anticancer activities by targeting these proteins.
Eupatilin, a naturally occurring flavonoid isolated from Artemisia princeps, has been reported to inhibit
the growth of human endometrial cancer cells via activating the Chk2/Cdc25C/Cdc2 pathway [8].
Dihydromyricetin, a flavonoid commonly found in grapes, berries, vegetables, herbs, and other plants,
induces G2/M phase cell cycle arrest of hepatocellular carcinoma cells through the Chk2/Cdc25C
pathway [31]. Genistein, an isoflavone found in soybeans and other plants, caused G2/M cell
cycle arrest in MCF-7 and MDA-MB-231 breast carcinoma cells via p21-mediated inhibition of
Cdc2 [32]. In the present study, we observed that kaempferol induced G2/M cell cycle arrest via
the Chk2/Cdc25C/Cdc2 pathway and Chk2/p21/Cdc2 pathway in A2780/CP70 cells. This result
is in accordance with a previous study. In that case, kaempferol was proven to activate G2 cell cycle
arrest through the Chk1/Chk2 pathway in human acute leukemia Jurkat T cells [33]. Our study and
previous studies implied that Chk2 might be a universal target for the cell cycle-interrupting activity
of flavonoids.
Death receptors refer to those members of the tumor necrosis factor receptor superfamily that
contain a death domain, such as Fas, DR4, and DR5. Among them, DR5 is regarded as one of the most
important anticancer targets. Up-regulation and/or activation of DR5 not only sensitizes cancer cells
to apoptosis [34,35], but also collapses tumor blood vessels to reduce tumor growth [36]. Recently,
DR5 was proven to act as a suppressor of human cancer cell invasion and metastasis [37]. Many studies
have shown that DR5 inducers or agonists exert anticancer activities in cell models and animal models.
Synergistic anticancer effects are also detected when DR5 inducers or agonists are combined with
traditional chemotherapeutics (e.g., doxorubicin) [38]. Unlike other death receptors, the expression of
Molecules 2018, 23, 1095 8 of 12
DR5 is much lower in normal tissues than in cancerous tissues [36,39], implying that targeting DR5
might induce cancer-specific cell death and cause few adverse effects in normal cells. In the present
study, kaempferol enhanced the expression of DR5, Fas, and FADD, the activity of Caspase-8 and
cleavage of PARP-1. Knockdown of DR5 partially rescued kaemferol-induced activation of the extrinsic
apoptotic pathway. Former studies illustrated that kaempferol increased the levels of membrane-bound
FAS ligand, decreased uncleaved caspase-8 and intact Bid, and increased caspase-8 activity in HT-29
human colon cancer cells [40]. In human colon cancer SW480 cells, kaempferol markedly up-regulated
tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors, DR5, and death receptor
4 (DR4) [41]. Kaempferol sensitized cancer cells to TRAIL-induced apoptosis via up-regulation of
death receptors [41]. One of the mechanisms in which kaempferol modulated death receptors was by
activating the reactive oxygen species-mediated p53/ ataxia telangiectasia mutated (ATM) signaling
pathway [42]. Another study indicated that the JNK/ ERK-CHOP pathway was also involved [43].
Our results supplied additional evidence that death receptor signaling pathway played an important
role in kaempferol-induced apoptosis.
4. Materials and Methods
4.1. Cell Culture and Reagents
Human ovarian carcinoma cell lines A2780/CP70 and human immortalized ovarian surface
epithelial cells (IOSE 364), were kind gifts from Dr. Bing-Hua Jiang at Thomas Jefferson University
and Dr. Auersperg at the University of British Columbia, respectively. Cells were cultured in RPMI
1640 medium (Sigma, St. Louis, MO, USA) incorporating 10% fetal bovine serum (FBS) (Invitrogen,
Grand Island, NY, USA). Cells were grown in a humidified incubator containing 5% CO2 at 37 ◦C.
Reagents: Kaempferol was purchased from Sigma. Dead Cell Apoptosis Kit with Annexin V Alexa
Fluor® 488 and propidium iodide (PI) was purchased from ThermoFisher Scientific (Waltham, MA,
USA). Caspase-Glo® 3/7 Assay Systems, Caspase-Glo® 8 Assay Systems and Caspase-Glo® 9 Assay
Systems were purchased from Promega (Madison, WI, USA). Antibodies against p21 Waf1/Cip1
(p21), p-Cdc25C (Ser 216), Cdc25C, p-Cdc2 (Tyr 15), Cdc2, Cyclin B1, p53, death receptor 5 (DR5),
Fas, and Fas-Associated protein with Death Domain (FADD) were purchased from Cell Signaling
Technology, Inc. (Danvers, MA, USA). Antibodies against phosphor-checkpoint kinase 2 (Chk2) (Thr68),
Chk2, poly [ADP-ribose] polymerase 1 (PARP-1), and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA).
4.2. Assessment of Cell Viability In Vitro
Cells were seeded into 96-well plates at a density of 104 cells per well in medium with 10% FBS.
After overnight growth, cells were treated with kaempferol for 48 h. Cell viability was measured
using the CellTiter 96® Aqueous One Solution Cell Proliferation Assay (Promega, Madison, WI, USA),
according to the manufacturer’s instructions. Cell viability was expressed as a percentage compared to
the control group.
4.3. Cell Cycle Analysis
Cells were treated with kaempferol for 48h. Then cells were harvested and fixed with cold
70% ethanol overnight. Cells were stained according to the manufacturer’s instructions. Data acquisition
and analysis were performed following flow cytometry with accompanying software (FACS Calibur,
version 5.1, BD Bioscience, San Jose, CA, USA).
4.4. Western Blot
Cells were treated with kaempferol for 48 h in 60 mm dishes and then harvested. The Western blot
assay was conducted according to a previously published method [44]. Protein bands were quantified
with the NIH ImageJ software (NIH), normalized to the corresponding GAPDH band for analysis.
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4.5. Transfection with Small Interfering RNA (siRNA)
Cells were seeded and incubated overnight. Then cells were transfected with control or
target-specific siRNA using jetPRIME™ DNA and siRNA transfection reagent (VWR International,
Radnor, PA, USA) according to the manufacturer’s protocol. After 24 h, cells were exposed to cell
culture medium containing kaempferol (0 or 40 µmol/ L) for another 48 h.
4.6. Apoptosis Analysis
Cells were treated with kaempferol for 48 h. Then cells were collected and stained with Annexin V
Alexa Fluor® 488 and propidium iodide (PI) according to the manufacturer’s instructions. Data acquisition
and analysis were performed following flow cytometry with accompanying software (FACS Calibur;
BD Bioscience, San Jose, CA, USA).
4.7. Caspase Activity Assay
Cells were seeded into 96-well plates at a density of 104 cells per well in medium with 10% FBS. After
overnight growth, cells were treated with kaempferol for 48 h. Caspase-3/7, Caspase-8, and Caspase-9
activities were detected using Caspase-Glo 3/7, Caspase-Glo 8 or Caspase-Glo 9 Assay kit (Promega),
respectively. Caspase activities were expressed as a percentage compared to the control group.
4.8. Statistical Analysis
All data were expressed as mean ± standard error of mean (SEM) from at least three independent
experiments. The results were analyzed with SPSS Version 18.0 for Windows (SPSS, Chicago, IL, USA)
using one-way analysis of variance (ANOVA) and a post hoc test (2-sided Dunnett’s test) to test both
overall differences and specific differences between each treatment and control. P values < 0.05 were
considered statistically significant.
5. Conclusions
Taken together, Chk2 and death receptors are pivotal anticancer targets of kaempferol (Figure 5).
Kaempferol induced G2/M cell cycle arrest via the Chk2/Cdc25C/Cdc2 pathway and Chk2/p21/Cdc2
pathway. Chk2 was not involved in kaempferol-induced apoptosis. Kaempferol mediated intrinsic
apoptosis via p53 in a Chk2-independent manner. It increased the expression of DR5 and Fas, resulting
in the activation of extrinsic apoptosis. Since A2780/CP70 cells are cisplatin-resistant, our results
suggested that kaempferol might help overcome cisplatin resistance in ovarian cancer. More studies
are required to verify this hypothesis.
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